{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:25:09Z","timestamp":1787181909084,"version":"build-2736575974"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Government of Catalonia Agency for Administration of University and Research Grants","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010552","name":"Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010552","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Spain Ministry of Science Innovation and Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.biopha.2026.119807","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T16:15:22Z","timestamp":1785255322000},"page":"119807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Urinary biomarkers in muscle-invasive bladder cancer: Current state and open opportunities for neoadjuvant chemotherapy response prediction and patient stratification"],"prefix":"10.1016","volume":"202","author":[{"given":"Gisela","family":"de Miguel-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicen\u00e7","family":"Ruiz de Porras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Font-Mor\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Font","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc E.","family":"Borr\u00e0s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Clos-Sansalvador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119807_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"Ca. Cancer J. Clin."},{"key":"10.1016\/j.biopha.2026.119807_bib2","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2026.119807_bib3","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/his.13734","article-title":"Staging of bladder cancer","volume":"74","author":"Magers","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.biopha.2026.119807_bib4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4103\/0970-1591.166445","article-title":"Non-muscle invasive bladder cancer risk stratification","volume":"31","author":"Isharwal","year":"2015","journal-title":"Indian. J. Urol."},{"key":"10.1016\/j.biopha.2026.119807_bib5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4111\/icu.20230006","article-title":"Perioperative systemic therapy in muscle invasive bladder cancer: current standard method, biomarkers and emerging strategies","volume":"64","author":"Kim","year":"2023","journal-title":"Investig. Clin. Urol."},{"key":"10.1016\/j.biopha.2026.119807_bib6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/diseases12030056","article-title":"The assessment of SF-36 Survey for quality-of-life measurement after radical cystectomy for muscle-invasive bladder cancer: a systematic review","volume":"12","author":"Barbos","year":"2024","journal-title":"Diseases"},{"key":"10.1016\/j.biopha.2026.119807_bib7","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3390\/jpm14040392","article-title":"Advances in urinary diversion: from cutaneous ureterostomy to orthotopic neobladder reconstruction\u2014a comprehensive review","volume":"14","author":"Barone","year":"2024","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.biopha.2026.119807_bib8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1590\/s1677-5538.ibju.2022.0405","article-title":"Perioperative mortality for radical cystectomy in the modern Era: experience from a tertiary referral center","volume":"49","author":"Sobhani","year":"2023","journal-title":"Int. Braz. J. Urol."},{"key":"10.1016\/j.biopha.2026.119807_bib9","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data","volume":"48","author":"Vale","year":"2005","journal-title":"Eur. Urol."},{"key":"10.1016\/j.biopha.2026.119807_bib10","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119807_bib11","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s12672-025-02796-6","article-title":"Neoadjuvant treatment patterns and biomarker selection in muscle-invasive bladder cancer","volume":"16","author":"He","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.biopha.2026.119807_bib12","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119807_bib13","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer","volume":"394","author":"Vulsteke","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119807_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.biopha.2026.119807_bib15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-022-01543-7","article-title":"Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments","volume":"21","author":"Lone","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2026.119807_bib16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.euf.2017.03.009","article-title":"Emerging utility of urinary cell-free nucleic acid biomarkers for prostate, bladder, and renal cancers","volume":"3","author":"Lin","year":"2017","journal-title":"Eur. Urol. Focus."},{"key":"10.1016\/j.biopha.2026.119807_bib17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119807_bib18","first-page":"41","article-title":"Urinary biomarkers in bladder cancer: a review of the current landscape and future directions","volume":"39","author":"Ng","year":"2021","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"10.1016\/j.biopha.2026.119807_bib19","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3390\/cancers16040803","article-title":"New perspectives on the role of liquid biopsy in bladder cancer: applicability to precision medicine","volume":"16","author":"Alberca-del Arco","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119807_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2024.100271","article-title":"Clinical utility of liquid biopsy in bladder cancer: the beginning of a new era","volume":"6","author":"Jia","year":"2024","journal-title":"J. Liq. Biopsy"},{"key":"10.1016\/j.biopha.2026.119807_bib21","article-title":"Detecting and monitoring bladder cancer with exfoliated cells in urine","volume":"12","author":"Li","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2026.119807_bib22","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.3390\/cancers12061400","article-title":"Urinary biomarkers in bladder cancer: where do we stand and potential role of extracellular vesicles","volume":"12","author":"Oliveira","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119807_bib23","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/iju.15338","article-title":"Urinary markers for bladder cancer diagnosis: a review of current status and future challenges","volume":"31","author":"Tomiyama","year":"2024","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.biopha.2026.119807_bib24","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/1878-0261.13628","article-title":"Unlocking the potential of tumor-derived DNA in urine for cancer detection: methodological challenges and opportunities","volume":"19","author":"Wever","year":"2025","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.biopha.2026.119807_bib25","doi-asserted-by":"crossref","first-page":"5646","DOI":"10.1158\/1078-0432.CCR-20-0401","article-title":"Noninvasive detection of urothelial carcinoma by cost-effective low-coverage whole-genome sequencing from urine-exfoliated cell DNA","volume":"26","author":"Zeng","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119807_bib26","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.18632\/oncotarget.6487","article-title":"Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119807_bib27","doi-asserted-by":"crossref","first-page":"6357","DOI":"10.2147\/CMAR.S186108","article-title":"Urinary exosomal expression of long non-coding RNAs as diagnostic marker in bladder cancer","volume":"10","author":"Yazarlou","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.biopha.2026.119807_bib28","doi-asserted-by":"crossref","first-page":"37500","DOI":"10.18632\/oncotarget.6061","article-title":"Urine BLCA-4 exerts potential role in detecting patients with bladder cancers: a pooled analysis of individual studies","volume":"6","author":"Cai","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119807_bib29","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MOU.0000000000000605","article-title":"Urinary biomarkers in bladder cancer: where do we stand?","volume":"29","author":"Bhat","year":"2019","journal-title":"Curr. Opin. Urol."},{"key":"10.1016\/j.biopha.2026.119807_bib30","first-page":"553","article-title":"Liquid biopsy testing in urological cancers: focus on urine","volume":"43","author":"Pisapia","year":"2025","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"10.1016\/j.biopha.2026.119807_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2025.100310","article-title":"Liquid biopsy: current advancements in clinical practice for bladder cancer","volume":"9","author":"Crocetto","year":"2025","journal-title":"J. Liq. Biopsy"},{"key":"10.1016\/j.biopha.2026.119807_bib32","doi-asserted-by":"crossref","first-page":"922","DOI":"10.7326\/M15-0997","article-title":"Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis","volume":"163","author":"Chou","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.biopha.2026.119807_bib33","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11934-017-0748-x","article-title":"Recent developments in the search for urinary biomarkers in bladder cancer","volume":"18","author":"Leiblich","year":"2017","journal-title":"Curr. Urol. Rep."},{"key":"10.1016\/j.biopha.2026.119807_bib34","first-page":"66.e25","article-title":"Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer","volume":"33","author":"Yafi","year":"2015","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"10.1016\/j.biopha.2026.119807_bib35","doi-asserted-by":"crossref","first-page":"6554","DOI":"10.21037\/tcr-20-1990","article-title":"Review of non-invasive urinary biomarkers in bladder cancer","volume":"9","author":"Lee","year":"2020","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119807_bib36","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J. Urol."},{"key":"10.1016\/j.biopha.2026.119807_bib37","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119807_bib38","article-title":"Real-world treatment patterns, recurrence, and overall survival of patients with muscle-invasive bladder cancer undergoing radical cystectomy in U.S. oncology practice","volume":"44","author":"Squires","year":"2026","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"10.1016\/j.biopha.2026.119807_bib39","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1007\/s00432-019-03035-6","article-title":"MicroRNAs in tumor samples and urinary extracellular vesicles as a putative diagnostic tool for muscle-invasive bladder cancer","volume":"145","author":"Baumgart","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119807_bib40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ctrv.2018.05.012","article-title":"Novel urinary biomarkers for the detection of bladder cancer: a systematic review","volume":"69","author":"Tan","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.biopha.2026.119807_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1008","article-title":"Non-invasive diagnosis and surveillance of bladder cancer with driver and passenger DNA methylation in a prospective cohort study","volume":"12","author":"Xiao","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.biopha.2026.119807_bib42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12916-023-02813-x","article-title":"Comprehensive proteomics and platform validation of urinary biomarkers for bladder cancer diagnosis and staging","volume":"21","author":"Vanarsa","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.biopha.2026.119807_bib43","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5584\/jiomics.v15i1.245","article-title":"Differential urinary proteomics and absolute protein quantification reveal biomarkers of muscle-invasive and non-muscle-invasive bladder cancer","volume":"15","author":"Montes","year":"2025","journal-title":"J. Integr. OMICS"},{"key":"10.1016\/j.biopha.2026.119807_bib44","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.3390\/curroncol29080430","article-title":"Integrative multi-omics analysis for the determination of non-muscle invasive vs. muscle invasive bladder cancer: a pilot study","volume":"29","author":"Yu","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.biopha.2026.119807_bib45","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1007\/s00345-022-04136-7","article-title":"LC\u2013MS metabolomics of urine reveals distinct profiles for non-muscle-invasive and muscle-invasive bladder cancer","volume":"40","author":"Oto","year":"2022","journal-title":"World J. Urol."},{"key":"10.1016\/j.biopha.2026.119807_bib46","first-page":"507","article-title":"Bladder cancer: diagnosis and treatment","volume":"96","author":"DeGeorge","year":"2017","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.biopha.2026.119807_bib47","doi-asserted-by":"crossref","DOI":"10.5489\/cuaj.5405","article-title":"Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma","volume":"13","author":"Duplisea","year":"2018","journal-title":"Can. Urol. Assoc. J."},{"key":"10.1016\/j.biopha.2026.119807_bib48","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4111\/icu.2020.61.4.390","article-title":"Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer","volume":"61","author":"Carvalho","year":"2020","journal-title":"Investig. Clin. Urol."},{"key":"10.1016\/j.biopha.2026.119807_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103795","article-title":"Neoadjuvant therapy for muscle-invasive bladder cancer: current clinical scenario, future perspectives, and unsolved questions","volume":"178","author":"Ruiz De Porras","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.biopha.2026.119807_bib50","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3233\/BLC-230015","article-title":"Predictive value of computed tomography following neoadjuvant chemotherapy for muscle invasive bladder cancer","volume":"9","author":"Alam","year":"2023","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.biopha.2026.119807_bib51","doi-asserted-by":"crossref","first-page":"9899","DOI":"10.3390\/ijms25189899","article-title":"Protein-based predictive biomarkers to personalize neoadjuvant therapy for bladder cancer\u2014a systematic review of the current status","volume":"25","author":"Bedore","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119807_bib52","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/cancers15010168","article-title":"Predicting complete response to neoadjuvant chemotherapy in muscle-invasive bladder cancer","volume":"15","author":"Miyagi","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119807_bib53","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.3390\/cancers14071692","article-title":"Molecular subtypes as a basis for stratified use of neoadjuvant chemotherapy for muscle-invasive bladder cancer\u2014a narrative review","volume":"14","author":"Sj\u00f6dahl","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119807_bib54","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eururo.2021.10.035","article-title":"Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes","volume":"81","author":"Sj\u00f6dahl","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.biopha.2026.119807_bib55","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2016.1056","article-title":"Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma","volume":"2","author":"Liu","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.biopha.2026.119807_bib56","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.eururo.2024.06.018","article-title":"Correlative analysis of ATM, RB1, ERCC2, and FANCC mutations and pathologic complete response after neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: results from the SWOG S1314 trial","volume":"86","author":"Plimack","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.biopha.2026.119807_bib57","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1038\/s41467-020-18640-0","article-title":"Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis","volume":"11","author":"Taber","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119807_bib58","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/1078-0432.CCR-20-2409","article-title":"A Randomized Phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695)","volume":"27","author":"Flaig","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119807_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104862","article-title":"Emerging biomarkers in bladder cancer: translating molecular advances into precision oncology","volume":"215","author":"Ferro","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.biopha.2026.119807_bib60","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-23-1860","article-title":"Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-up","volume":"29","author":"Lindskrog","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119807_bib61","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/1078-0432.CCR-22-3250","article-title":"Cell-free urine and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle-invasive bladder cancer","volume":"29","author":"Christensen","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119807_bib62","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12935-025-03707-z","article-title":"Prognostic and predictive role of circulating tumor DNA detection in patients with muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"25","author":"Gao","year":"2025","journal-title":"Cancer Cell. Int."},{"key":"10.1016\/j.biopha.2026.119807_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2026.03.005","article-title":"Blood and urine circulating tumor DNA in urothelial bladder cancer: state of the art and clinical perspective","author":"Duquesne","year":"2026","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.biopha.2026.119807_bib64","article-title":"Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: a cohort study","volume":"18","author":"Chauhan","year":"2021","journal-title":"PLOS Med."},{"key":"10.1016\/j.biopha.2026.119807_bib65","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00362","article-title":"Urine biopsy as dynamic biomarker to enhance clinical staging of bladder cancer in radical cystectomy candidates","author":"Satyal","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.biopha.2026.119807_bib66","doi-asserted-by":"crossref","DOI":"10.1148\/rg.230149","article-title":"Practical guide to VI-RADS: MRI protocols, lesion characterization, and pitfalls","volume":"44","author":"F\u00e1vero Prietto Dos Santos","year":"2024","journal-title":"RadioGraphics"},{"key":"10.1016\/j.biopha.2026.119807_bib67","doi-asserted-by":"crossref","DOI":"10.1177\/17562872211039583","article-title":"Multiparametric magnetic resonance imaging for bladder cancer: a comprehensive systematic review of the Vesical Imaging-Reporting and Data System (VI-RADS) performance and potential clinical applications","volume":"13","author":"S\u00e9guier","year":"2021","journal-title":"Ther. Adv. Urol."},{"key":"10.1016\/j.biopha.2026.119807_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1019391","article-title":"Urine exosomes as biomarkers in bladder cancer diagnosis and prognosis: from functional roles to clinical significance","volume":"12","author":"Lee","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2026.119807_bib69","article-title":"Urinary exosomes: potential diagnostic markers and application in bladder cancer","volume":"10","author":"Liu","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.biopha.2026.119807_bib70","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.euo.2023.03.008","article-title":"Cell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer in SWOG S1314","volume":"6","author":"Lu","year":"2023","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.biopha.2026.119807_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1441883","article-title":"Urinary mRNA-based biomarkers for non-muscle-invasive bladder cancer: a mini-review","volume":"14","author":"Coelho","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2026.119807_bib72","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-22577-3","article-title":"Urine stabilization and normalization strategies favor unbiased analysis of urinary EV content","volume":"12","author":"Vago","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119807_bib73","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/ejcn.2015.217","article-title":"Equivalence of afternoon spot and 24-h urinary hydration biomarkers in free-living healthy adults","volume":"70","author":"Bottin","year":"2016","journal-title":"Eur. J. Clin. Nutr."},{"key":"10.1016\/j.biopha.2026.119807_bib74","doi-asserted-by":"crossref","first-page":"89","DOI":"10.11613\/BM.2014.011","article-title":"Preanalytical requirements of urinalysis","author":"Delanghe","year":"2014","journal-title":"Biochem. Med."},{"key":"10.1016\/j.biopha.2026.119807_bib75","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/jalm\/jfab082","article-title":"Sample processing and stability for urine biomarker studies","volume":"6","author":"Chang","year":"2021","journal-title":"J. Appl. Lab. Med."},{"key":"10.1016\/j.biopha.2026.119807_bib76","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3390\/cancers12040859","article-title":"Comparative analysis of urine fractions for optimal bladder cancer detection using DNA methylation markers","volume":"12","author":"Hentschel","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119807_bib77","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3390\/genes14071415","article-title":"Capturing the kidney transcriptome by urinary extracellular vesicles\u2014from pre-analytical obstacles to biomarker research","volume":"14","author":"Barreiro","year":"2023","journal-title":"Genes"},{"key":"10.1016\/j.biopha.2026.119807_bib78","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119807_bib79","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","article-title":"Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.biopha.2026.119807_bib80","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.3390\/cancers17162640","article-title":"Urinary microRNAs as prognostic biomarkers for predicting the efficacy of immune checkpoint inhibitors in patients with urothelial carcinoma","volume":"17","author":"Hirasawa","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119807_bib81","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/bju.16610","article-title":"Long-term quality of life in patients with bladder cancer following radical cystectomy","volume":"135","author":"Akdemir","year":"2025","journal-title":"BJU Int."},{"key":"10.1016\/j.biopha.2026.119807_bib82","doi-asserted-by":"crossref","first-page":"5830","DOI":"10.3390\/cancers15245830","article-title":"Health related quality of life in patients with bladder cancer receiving a radical cystectomy","volume":"15","author":"Mastroianni","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119807_bib83","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.euf.2025.06.009","article-title":"Urinary tumor DNA\u2013based liquid biopsy in bladder cancer management: a systematic review","volume":"11","author":"Lee","year":"2025","journal-title":"Eur. Urol. Focus."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:53:48Z","timestamp":1787180028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226008437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":83,"alternative-id":["S0753332226008437"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119807","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urinary biomarkers in muscle-invasive bladder cancer: Current state and open opportunities for neoadjuvant chemotherapy response prediction and patient stratification","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119807","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119807"}}